LivaNova (NASDAQ:LIVN) Downgraded to Peer Perform Rating by Wolfe Research

LivaNova (NASDAQ:LIVN) was downgraded by stock analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating in a note issued to investors on Wednesday, MarketBeat reports.

A number of other research analysts have also commented on the stock. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Buy” and a consensus price target of $64.20.

LivaNova Trading Down 1.3 %

Shares of LIVN stock opened at $40.93 on Wednesday. The company’s fifty day simple moving average is $47.52 and its two-hundred day simple moving average is $49.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a 1 year low of $40.37 and a 1 year high of $64.47. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of 97.45 and a beta of 1.00.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by insiders.

Institutional Trading of LivaNova

Several hedge funds have recently added to or reduced their stakes in LIVN. State of Alaska Department of Revenue lifted its stake in LivaNova by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the last quarter. abrdn plc raised its stake in shares of LivaNova by 43.8% during the third quarter. abrdn plc now owns 232,025 shares of the company’s stock valued at $12,191,000 after acquiring an additional 70,618 shares during the last quarter. Emerald Advisers LLC raised its stake in shares of LivaNova by 2.1% during the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock valued at $36,542,000 after acquiring an additional 14,302 shares during the last quarter. Atria Investments Inc raised its stake in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after acquiring an additional 331 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D raised its stake in shares of LivaNova by 38.3% during the third quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock valued at $2,235,000 after acquiring an additional 11,782 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.